The latest price target for Virax Biolabs Group (NASDAQ:VRAX) was reported by HC Wainwright & Co. on March 31, 2025. The analyst firm set a price target for $3.00 expecting VRAX to rise to within 12 months (a possible 200.00% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Virax Biolabs Group (NASDAQ:VRAX) was provided by HC Wainwright & Co., and Virax Biolabs Group initiated their buy rating.

There is no last upgrade for Virax Biolabs Group

There is no last downgrade for Virax Biolabs Group.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Virax Biolabs Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Virax Biolabs Group was filed on March 31, 2025 so you should expect the next rating to be made available sometime around March 31, 2026.

While ratings are subjective and will change, the latest Virax Biolabs Group (VRAX) rating was a initiated with a price target of $0.00 to $3.00. The current price Virax Biolabs Group (VRAX) is trading at is $1.00, which is within the analyst’s predicted range.